Harbin Gloria Pharmaceuticals Total Liabilities
Harbin Gloria Pharmaceuticals total liabilities. Based on the latest financial reports, Harbin Gloria Pharmaceuticals (002437) has total liabilities worth CN¥735.96 Million CNY (≈ $107.69 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Harbin Gloria Pharmaceuticals to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Harbin Gloria Pharmaceuticals (2007–2025)
Total liabilities of Harbin Gloria Pharmaceuticals from 2007 to 2025. This chart illustrates how Harbin Gloria Pharmaceuticals's total liabilities have evolved over time, based on quarterly financial data. Explore Harbin Gloria Pharmaceuticals (002437) long-term investment share to see how much of total assets are deployed in long-term investments.
Harbin Gloria Pharmaceuticals Competitors by Total Liabilities
The table below lists competitors of Harbin Gloria Pharmaceuticals ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rigol Technologies Co. Ltd. A
SHG:688337
|
China | CN¥371.38 Million |
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
|
China | CN¥13.05 Billion |
|
Superior Plus Corp
TO:SPB
|
Canada | CA$2.78 Billion |
|
Brookline Bancorp Inc
NASDAQ:BRKL
|
USA | $10.31 Billion |
|
Akasha Wira International Tbk
JK:ADES
|
Indonesia | Rp516.28 Billion |
|
Yueyang Forest & Paper Co Ltd
SHG:600963
|
China | CN¥12.77 Billion |
|
Anhui Andeli Department Store Co Ltd
SHG:603031
|
China | CN¥2.74 Billion |
|
Redcare Pharmacy NV
F:RDC
|
Germany | €735.10 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Harbin Gloria Pharmaceuticals's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 002437 total assets.
Liquidity & Leverage Metrics
Harbin Gloria Pharmaceuticals Total Liabilities Ratios Explained
Harbin Gloria Pharmaceuticals total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Harbin Gloria Pharmaceuticals's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Harbin Gloria Pharmaceuticals (2007–2025)
The table below shows the annual total liabilities of Harbin Gloria Pharmaceuticals from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥825.00 Million ≈ $120.72 Million |
-3.20% |
| 2024-12-31 | CN¥852.26 Million ≈ $124.71 Million |
-40.91% |
| 2023-12-31 | CN¥1.44 Billion ≈ $211.04 Million |
-39.16% |
| 2022-12-31 | CN¥2.37 Billion ≈ $346.90 Million |
-12.72% |
| 2021-12-31 | CN¥2.72 Billion ≈ $397.47 Million |
+5.14% |
| 2020-12-31 | CN¥2.58 Billion ≈ $378.03 Million |
-46.39% |
| 2019-12-31 | CN¥4.82 Billion ≈ $705.18 Million |
-5.20% |
| 2018-12-31 | CN¥5.08 Billion ≈ $743.86 Million |
+5.65% |
| 2017-12-31 | CN¥4.81 Billion ≈ $704.09 Million |
+4.15% |
| 2016-12-31 | CN¥4.62 Billion ≈ $676.04 Million |
-4.66% |
| 2015-12-31 | CN¥4.85 Billion ≈ $709.06 Million |
+166.22% |
| 2014-12-31 | CN¥1.82 Billion ≈ $266.35 Million |
+291.77% |
| 2013-12-31 | CN¥464.60 Million ≈ $67.99 Million |
+127.98% |
| 2012-12-31 | CN¥203.79 Million ≈ $29.82 Million |
+77.35% |
| 2011-12-31 | CN¥114.91 Million ≈ $16.81 Million |
+55.85% |
| 2010-12-31 | CN¥73.73 Million ≈ $10.79 Million |
-52.42% |
| 2009-12-31 | CN¥154.95 Million ≈ $22.67 Million |
+81.94% |
| 2008-12-31 | CN¥85.17 Million ≈ $12.46 Million |
+10.39% |
| 2007-12-31 | CN¥77.15 Million ≈ $11.29 Million |
-- |
About Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd w… Read more